.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Citi
McKinsey
Medtronic
AstraZeneca
Deloitte
Federal Trade Commission
QuintilesIMS
Fish and Richardson
Merck

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,232,264

« Back to Dashboard

Which drugs does patent 8,232,264 protect, and when does it expire?


Patent 8,232,264 protects VANOS and is included in one NDA. There has been one Paragraph IV challenge on Vanos.

This patent has eleven patent family members in nine countries.

Summary for Patent: 8,232,264

Title:Compositions and methods for enhancing corticosteroid delivery
Abstract: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70.
Inventor(s): Gans; Eugene H. (Westport, CT), Wortzman; Mitchell S. (Scottsdale, AZ)
Assignee: Medicis Pharmaceutical Corporation (Scottsdale, AZ)
Application Number:12/322,346
Patent Claim Types:
see list of patent claims
Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Medicis
VANOS
fluocinonide
CREAM;TOPICAL021758-001Feb 11, 2005ABRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,232,264

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,765,001 Compositions and methods for enhancing corticosteroid delivery► Subscribe
7,771,733Compositions and methods for enhancing corticosteroid delivery► Subscribe
7,220,424Compositions and methods for enhancing corticosteroid delivery► Subscribe
7,217,422Compositions and methods for enhancing corticosteroid delivery► Subscribe
7,794,738Compositions and methods for enhancing corticosteroid delivery► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,232,264

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
MexicoPA04006014► Subscribe
Japan2010280689► Subscribe
Japan2005524614► Subscribe
Israel162581► Subscribe
European Patent Office2363150► Subscribe
European Patent Office1465636► Subscribe
China1617730► Subscribe
Canada2471041► Subscribe
Brazil0215254► Subscribe
Australia2002360589► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
AstraZeneca
Express Scripts
Mallinckrodt
Chubb
Citi
Fuji
US Army
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot